# HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer

> **NCT06014190** · PHASE2 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 460 (estimated)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Endometrial Cancer

## Interventions

- **DRUG:** HS-20089

## Key facts

- **NCT ID:** NCT06014190
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 460 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06014190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06014190, "HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06014190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*